BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26294714)

  • 21. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rejection of leukemic cells requires antigen-specific T cells with high functional avidity.
    Vincent K; Hardy MP; Trofimov A; Laumont CM; Sriranganadane D; Hadj-Mimoune S; Salem Fourati I; Soudeyns H; Thibault P; Perreault C
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):37-45. PubMed ID: 24161924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CARs in chronic lymphocytic leukemia -- ready to drive.
    Hosing C; Kebriaei P; Wierda W; Jena B; Cooper LJN; Shpall E
    Curr Hematol Malig Rep; 2013 Mar; 8(1):60-70. PubMed ID: 23225251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
    Hillerdal V; Ramachandran M; Leja J; Essand M
    BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
    Zheng S; Asnani M; Thomas-Tikhonenko A
    Cancer J; 2019; 25(3):217-222. PubMed ID: 31135529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
    Rogosic S; Ghorashian S
    Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 36. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Lulla PD; Mamonkin M; Brenner MK
    Cancer J; 2019; 25(3):199-207. PubMed ID: 31135527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
    Badar T; Shah NN
    Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy with T cells bearing chimeric antitumor receptors.
    Paillard F
    Hum Gene Ther; 1999 Jan; 10(2):151-3. PubMed ID: 10022540
    [No Abstract]   [Full Text] [Related]  

  • 39. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is antigen specificity the key to efficient adoptive T-cell therapy?
    Labarriere N; Khammari A; Lang F; Dreno B
    Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.